Nipocalimab is Making Progress in Four Clinical Trials for Autoimmune and Alloimmune Conditions
source: pixabay.com

Nipocalimab is Making Progress in Four Clinical Trials for Autoimmune and Alloimmune Conditions

An investigative therapy for hemolytic disease of the fetus and newborn (HDFN) has just received the FDA's Rare Pediatric Disease and Orphan Drug Designations. This therapy is called nipocalimab and…

Continue Reading Nipocalimab is Making Progress in Four Clinical Trials for Autoimmune and Alloimmune Conditions
Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study
source: pixabay.com

Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study

According to a story from Myasthenia Gravis News, a recent case report describes a unique case of a 60 year old male multiple myeloma patient. After receiving treatment for the…

Continue Reading Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study
June is Myasthenia Gravis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

June is Myasthenia Gravis Awareness Month: Spreading Rare Disease Awareness

June is recognized as Myasthenia Gravis Awareness Month. Primarily organized by the Myasthenia Gravis Foundation of America (MGFA), this event is focused on spreading awareness as well as boosting efforts…

Continue Reading June is Myasthenia Gravis Awareness Month: Spreading Rare Disease Awareness
Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
source: pixabay.com

Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis

  According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…

Continue Reading Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients
source: pixabay.com

New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients

  New information, speculation, statistics, and predictions about COVID-19 are hitting the internet every day. Yet neurologists are attempting to answer their patients’ questions without having sufficient data that would…

Continue Reading New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients
Here’s How Coronavirus/COVID-19 Could Impact Multiple Sclerosis Patients
source: pixabay.com

Here’s How Coronavirus/COVID-19 Could Impact Multiple Sclerosis Patients

According to a story from NeurologyLive, patients being treated for autoimmune diseases such as multiple sclerosis (MS) or myasthenia gravis could be at heightened risk of infection with coronavirus because…

Continue Reading Here’s How Coronavirus/COVID-19 Could Impact Multiple Sclerosis Patients

Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes

Firdapse, or amifampridine phosphate, is a medication currently approved for Lambert-Eaton myasthenic syndrome, or LEMS. However, Catalyst Pharmaceuticals has been working to evaluate if it can aid other neurological and…

Continue Reading Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes

“When You Have to, You Can:” a Myasthenia Gravis Story From the Czech Republic

"It’s like when you suddenly shut off control over your muscles. Your will can’t affect it at all. “I say that I’m a ‘physical schizophrenic,’ and I can only do…

Continue Reading “When You Have to, You Can:” a Myasthenia Gravis Story From the Czech Republic
Close Menu